Skip to main content

LaBarre Michael J.'s Form 4 filing

Halozyme Therapeutics, Inc. (HALO) · filed Aug 21, 2024

Accession no.
0001415889-24-021850
Filed
Aug 21, 2024
Trade date
Aug 20-21, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.23M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
LaBarre Michael J.CIK 0001507174Officer (SVP, CHIEF TECHNICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 20, 2024Common StockMOption exerciseAcquired+10,000$16.65+$166,500178,176Direct
Aug 20, 2024Common StockSSaleDisposed−10,000$61.06−$610,600168,176Direct
Aug 21, 2024Common StockMOption exerciseAcquired+10,000$16.65+$166,500178,176Direct
Aug 21, 2024Common StockSSaleDisposed−9,900$61.74−$611,226168,276Direct
Aug 21, 2024Common StockSSaleDisposed−100$62.34−$6,234168,176Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 20, 2024Common StockMOption exerciseDisposed−10,000$0.00$041,861Direct
Aug 21, 2024Common StockMOption exerciseDisposed−10,000$0.00$031,861Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)